

BANGLADESH CRISIS
GO FOR INTENSIVE REENGAGEMENT

UPHAAR TO GOA
NO LESSONS LEARNT FROM FIRES

JOURNALISM WITH A HUMAN TOUCH

www.theweek.in

f TheWeekMag

ⓧ TheWeekLive

₹ 80

**THE NEW HUB
OF HISTORY**
YOUNG RESEARCHERS
CHANGE THE SCRIPT
IN TAMIL NADU

AGATHA CHRISTIE
HOW HER DETECTIVE
NOVELS REFLECTED
HER LIFE

THE WEEK

JANUARY 4, 2016

PREMIUM LIQUOR

FADING COLONIAL HANGOVER

Indian brands join
the world's
finest spirits



9 770975 227702



Mr Sachidanand Upadhyay
Managing Director

Lord's Mark Industries Puts India on the Global MedTech Map

In India's fast-evolving healthcare landscape, few companies have mirrored the country's transformation as compellingly as Lord's Mark Industries Ltd. (LMIL). Over 27 years, LMIL has evolved from a promising venture into one of India's most future-ready business groups—one that stands at the intersection of healthcare innovation, technology, and sustainable growth.

At a time when global healthcare is being reshaped by the demand for affordability and accessibility, LMIL has aligned itself with India's national ambition—to emerge as a global MedTech and diagnostics powerhouse. With a growing presence across biotechnology, medical diagnostics, and advanced medical devices, the company has built an integrated ecosystem that brings together research, manufacturing, and digital health intelligence.

Aligning Vision with National Priorities

The company's trajectory reflects a rare clarity of purpose: to use technology to democratize healthcare. Over the last decade, LMIL has directed nearly all of its innovation and investment into healthcare, building a model that combines India's strengths in R&D, engineering, and cost efficiency with global standards of precision and compliance.

Its growth aligns closely with the country's Make in India and Atmanirbhar Bharat (self-reliant India) missions. LMIL's facilities comply with US FDA, ISO 13485:2016, WHO-GMP, and CDSCO standards—placing it among the select few Indian MedTech manufacturers trusted globally for quality, reliability, and scalability.

By securing US FDA registration in 2025 for its surgical consumables, orthopedic supports, and hygiene products, the company joined the elite club of Indian manufacturers catering to regulated markets such as the United States, Europe, and the Middle East. This milestone not only validates its technological depth but also reinforces India's growing influence in the global healthcare supply chain.

Healthcare Innovation as Core Strategy

While diversification remains a strategic strength, healthcare has become LMIL's defining identity. The company's innovations span diagnostics, genomics, MedTech, and preventive health, each contributing to a larger mission of transforming care delivery.

Its Renalyx ecosystem represents one of India's most ambitious healthcare initiatives—an AI-powered kidney care platform that combines early disease detection, smart dialysis machines, and analytics-based patient monitoring. Designed for accessibility, it addresses the gap in chronic kidney disease treatment, especially in rural areas.

In the realm of genomics, One DNA has pioneered saliva-based genetic testing in India, offering individuals insights into predispositions for diseases such as cancer, cardiovascular disorders, and diabetes. This shift from curative to predictive medicine reflects LMIL's long-term focus on personalized and preventive healthcare.

The company's collaboration with IIT Bombay has led to the development of advanced testing technologies—from sickle cell detection to oral cancer screening using optical spectroscopy—capable of delivering near-perfect accuracy at the point of care. These innovations exemplify India's growing capacity to develop homegrown solutions for complex healthcare challenges.

Building India's MedTech Manufacturing Powerhouse

At the operational core of LMIL lies a state-of-the-art manufacturing hub in Dadra & Nagar Haveli, integrating five divisions across surgical, rehabilitation, orthopedic, and hygiene products. Equipped with automated machinery, advanced QC systems, and real-time logistics tracking, the plant demonstrates the sophistication of modern Indian manufacturing.

Every process—from material weaving and adhesive coating to product validation—adheres to strict global norms. The result is a product portfolio that meets both clinical precision and cost-efficiency benchmarks demanded by international markets.

LMIL's forward momentum continues with plans to establish Asia's largest

biochemistry reagents facility by 2027, followed by the continent's largest medical device manufacturing plant in 2028. These facilities are designed to scale innovation—enabling India to not only meet domestic healthcare demands but also serve as an export hub for the world.

To support these expansions, LMIL is exploring a global capital raise and dual listing on NASDAQ and the Bombay Stock Exchange (BSE). This international strategy underscores the company's confidence in India's ability to compete at par with established MedTech nations such as the US, Japan, and Germany.



Recognition on the Global Stage

LMIL's achievements have not gone unnoticed internationally. In 2025, the company received the 'Innovation in Diagnostic Devices' Award at the Indo-European Business Forum (IEBF) in London, held at the House of Lords. The recognition marked LMIL as the first Indian diagnostics company to receive the honour—a symbolic endorsement of India's rise as a source of innovation rather than imitation.

The event also reflected a broader shift in global perception: Indian companies like LMIL are no longer viewed as manufacturing outsourcers but as original innovators capable of developing, producing, and exporting high-precision MedTech solutions to the world.

LMIL has also achieved a defining milestone in India's med-tech landscape by receiving the license to manufacture Class C World's First AI-Based Smart

Hemodialysis Machines from the Central Drugs Standard Control Organisation (CDSCO), a critical step that significantly strengthens the country's self-reliance in life-saving healthcare technology.

Sustainability, Scale, and Social Purpose

What distinguishes LMIL is its ability to scale with conscience. Sustainability underpins its operations—from eco-efficient manufacturing practices and waste minimization to the use of predictive logistics systems that reduce carbon footprint through optimized routing and packaging.

Every step, from R&D to dispatch, is governed by a six-step Quality Excellence Framework, ensuring consistency, safety, and continuous improvement. This operational discipline has helped LMIL integrate speed with reliability, a balance critical in global supply chains.

But beyond infrastructure and innovation, LMIL's true strength lies in its purpose-driven culture—one that sees healthcare not just as a business but as a societal responsibility. By focusing on affordability and access, the company is aligning commercial success with human impact.

The Road Ahead

As LMIL expands its international operations through its U.S. subsidiary, Lords Mark Global LLC, and deepens its presence across South Asia, its role as a MedTech catalyst for emerging economies is becoming increasingly evident.

Its vision for the coming decade is clear—to make India not only a manufacturing base but a global center for medical innovation and technology exports.

By combining R&D excellence, regulatory rigor, and a deeply human approach to healthcare, Lords Mark Industries is proving that India's next global export won't just be technology—it will be trust.